Skip to main content
European Commission logo print header

International Clinical Validation of Radiomics Artificial Intelligence for Breast Cancer Treatment Planning

Descrizione del progetto

Uno studio internazionale volto a convalidare l’intelligenza artificiale per la previsione della risposta al trattamento nel carcinoma mammario

La radiomica è un approccio quantitativo all’imaging medico che estrae informazioni non accessibili per mezzo dell’ispezione visiva convenzionale di immagini generate, specialmente in oncologia. L’obiettivo del progetto RadioVal, finanziato dall’UE, è valutare le potenzialità della radiomica ai fini della previsione della risposta alla chemioterapia neoadiuvante in pazienti con carcinoma mammario, utilizzando l’IA. Il progetto si avvarrà di ampi archivi di imaging e risultati prodotti da precedenti progetti finanziati dall’UE. Inoltre, RadioVal attuerà una valutazione poliedrica degli strumenti radiomici basati sull’IA in otto ospedali di tutta Europa e non solo, per testarne la solidità tecnica, l’equità algoritmica, la fruibilità e l’accettazione in ambito clinico. I risultati dovrebbero aumentare la fiducia nel processo decisionale clinico basato sull’IA, ridurre l’eccesso di trattamento e migliorare l’esito per i pazienti con carcinoma mammario.

Obiettivo

Breast cancer is now the most common cancer worldwide, surpassing lung cancer in 2020 for the first time. It is responsible for almost 30% of all cancers in women and current trends show its increasing incidence. Neoadjuvant chemotherapy (NAC) has shown promise in reducing mortality for advanced cases, but the therapy is associated with a high rate of over-treatment, as well as with significant side effects for the patients. For predicting NAC respondents and improving patient selection, artificial intelligence (AI) approaches based on radiomics have shown promising preclinical evidence, but existing studies have mostly focused on evaluating model accuracy, all-too-often in homogeneous populations.

RadioVal is the first multi-centre, multi-continental and multi-faceted clinical validation of radiomics-driven estimation of NAC response in breast cancer. The project builds on the repositories, tools and results of five EU-funded projects from the AI for Health Imaging (AI4HI) Network, including a large multi-centre cancer imaging dataset on NAC treatment in breast cancer. To test applicability as well as transferability, the validation with take place in eight clinical centres from three high-income EU countries (Sweden, Austria, Spain), two emerging EU countries (Poland, Croatia), and three countries from South America (Argentina), North Africa (Egypt) and Eurasia (Turkey).

RadioVal will develop a comprehensive and standardised methodological framework for multi-faceted radiomics evaluation based on the FUTURE-AI Guidelines, to assess Fairness, Universality, Traceability, Usability, Robustness and Explainability. Furthermore, the project will introduce new tools to enable transparent and continuous evaluation and monitoring of the radiomics tools over time. The RadioVal study will be implemented through a multi-stakeholder approach, taking into account clinical and healthcare needs, as well as socio-ethical and regulatory requirements from day one.

æ

Coordinatore

UNIVERSITAT DE BARCELONA
Contribution nette de l'UE
€ 801 250,00
Indirizzo
Gran via de les corts catalanes 585
08007 Barcelona
Spagna

Mostra sulla mappa

Regione
Este Cataluña Barcelona
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Altri finanziamenti
€ 0,00

Partecipanti (15)